Differences in B-Cell Immunophenotypes and Neutralizing Antibodies Against SARS-CoV-2 After Administration of BNT162b2 (Pfizer-BioNTech) Vaccine in Individuals with and without Prior COVID-19 - A Prospective Cohort Study.
José Javier Morales-NúñezMariel García-ChagollánJosé Francisco Munoz-ValleSaúl Alberto Díaz PérezPaola Carolina Torres-HernándezSaraí Citlalic Rodríguez-ReyesGuillermo Santoscoy-AscencioJosé Julio Sierra García de QuevedoJorge Hernández-BelloPublished in: Journal of inflammation research (2022)
BNT162b2 vaccine induces changes in B cell subpopulations, especially generating plasma cells and producing neutralizing antibodies against SARS-CoV-2. However, the previous infection with SARS-CoV-2 does not significantly alter the dynamics of these subpopulations but induces more rapid and optimal antibody production.